@article{e4957200154d476f916d65a085102c55,
title = "Mayo-PACC: A parsimonious preclinical Alzheimer's disease cognitive composite comprised of public-domain measures to facilitate clinical translation",
abstract = "Introduction: We aimed to define a Mayo Preclinical Alzheimer's disease Cognitive Composite (Mayo-PACC) that prioritizes parsimony and use of public domain measures to facilitate clinical translation. Methods: Cognitively unimpaired participants aged 65 to 85 at baseline with amyloid PET imaging were included, yielding 428 amyloid negative (A-) and 186 amyloid positive (A+) individuals with 7 years mean follow-up. Sensitivity to amyloid-related cognitive decline was examined using slope estimates derived from linear mixed models (difference in annualized change across A+ and A- groups). We compared differences in rates of change between Mayo-PACC and other composites (A+ > A- indicating more significant decline in A+). Results: All composites showed sensitivity to amyloid-related longitudinal cognitive decline (A+ > A- annualized change p < 0.05). Comparisons revealed that Mayo-PACC (AVLT sum of trials 1-5+6+delay, Trails B, animal fluency) showed comparable longitudinal sensitivity to other composites. Discussion: Mayo-PACC performs similarly to other composites and can be directly translated to the clinic.",
keywords = "ADCS-PACC, aging, amyloid, biomarker, cognitive decline, cognitive outcome measure, embedded pragmatic clinical trials, global cognition, longitudinal, neuropsychology, PACC-R, practice effect, reliability, validity",
author = "Stricker, {Nikki H.} and Twohy, {Erin L.} and Albertson, {Sabrina M.} and Karstens, {Aimee J.} and Kremers, {Walter K.} and Machulda, {Mary M.} and Fields, {Julie A} and Jack, {Clifford R Jr.} and Knopman, {David S} and Mielke, {Michelle M} and Petersen, {Ronald C.}",
note = "Funding Information: The following disclosures are present, outside the scope of this work: NHS has received research support from NIH, Biogen and Lundbeck. MMMi has consulted for Biogen, Eli Lilly, Lab Corp and Merck and receives research support from NIH. MMMa receives research support from NIH. DSK serves on a Data Safety Monitoring Board for the DIAN‐TU study and is an investigator in clinical trials sponsored by Lilly Pharmaceuticals, Biogen, and the University of Southern California. RCP has served as a consultant for Hoffman‐La Roche Inc., Merck Inc., Genentech Inc., Biogen Inc., Eisai, Inc. and Nestle, Inc. He also receives NIH support. CRJ serves on an independent data monitoring board for Roche, has served as a speaker for Eisai, and consulted for Biogen, but he receives no personal compensation from any commercial entity. CRJ receives research support from NIH, the GHR Foundation and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. Funding Information: This work was supported by the Rochester Epidemiology Project (R01 AG034676), the National Institutes of Health (grant numbers P50 AG016574, P30 AG062677, U01 AG006786, and R01 AG041851, R37 AG011378, RF1 AG55151, R21 AG073967), the Robert Wood Johnson Foundation, The Elsie and Marvin Dekelboum Family Foundation, GHR, Alzheimer's Association, and the Mayo Foundation for Medical Education and Research. The authors wish to thank the participants and staff at the Mayo Clinic Study of Aging. Publisher Copyright: {\textcopyright} 2022 Mayo Foundation for Medical Education and Research. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",
year = "2022",
doi = "10.1002/alz.12895",
language = "English (US)",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
}